SOUTH SAN FRANCISCO, Calif. - Quince Therapeutics, Inc. (NASDAQ: QNCX), a biotech firm focused on rare diseases, recently presented safety data from its Phase 3 ATTeST trial at the 53rd Child Neurology Society Annual Meeting. The study involved EryDex, an investigational treatment for Ataxia-Telangiectasia (A-T), a rare neurodegenerative condition.
The poster presentation highlighted that EryDex was generally well-tolerated in the trial, with most treatment-emergent adverse events (TEAEs) being mild to moderate. Importantly, side effects typically associated with chronic steroid use were not observed in patients. The study reported three patients discontinuing due to adverse events, with one serious adverse event deemed unlikely related to the treatment.
Quince Therapeutics' CEO, Dirk Thye, M.D., expressed optimism about EryDex's potential, noting that the safety profile supports further evaluation for A-T treatment. The company's pivotal Phase 3 NEAT study is currently enrolling patients in the U.S. and Europe, with topline results expected in late 2025.
The NEAT trial aims to assess EryDex's neurological effects in A-T patients and operates under a Special Protocol Assessment with the FDA. Quince has also received Fast Track designation for EryDex, indicating its potential to meet an unmet medical need.
A-T is a genetic disorder causing neurological decline and immunodeficiency, with patients often becoming wheelchair-bound by adolescence. There are approximately 4,600 diagnosed cases in the U.S. and an estimated 5,000 in the U.K. and EU4 countries, with no approved treatments available.
EryDex utilizes Quince's proprietary AIDE technology, which encapsulates the drug in a patient's own red blood cells to potentially reduce the adverse effects of chronic corticosteroid use.
Quince Therapeutics is a late-stage biotech company dedicated to developing treatments for rare diseases. The information in this article is based on a press release statement.
In other recent news, Quince Therapeutics has been recognized by both Rodman & Renshaw and EF Hutton, who initiated coverage on the company with a Buy rating. The analysts' focus was on the company's innovative approach to treating Ataxia-Telangiectasia (A-T), a rare genetic disorder, with its leading therapeutic candidate, EryDex. Quince Therapeutics has released promising data from its Phase 3 ATTeST clinical trial, indicating a favorable safety profile and a positive effect in a subset of patients, particularly children aged six to nine. However, the company faces a potential delisting from The Nasdaq Global Select Market due to non-compliance with the minimum bid price requirement, with a deadline until December 17, 2024, to regain compliance. On a positive note, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Quince's EryDex System, marking a significant regulatory milestone. These are among the recent developments surrounding Quince Therapeutics, as the company continues to innovate and navigate regulatory challenges.
InvestingPro Insights
As Quince Therapeutics (NASDAQ: QNCX) advances its EryDex treatment for Ataxia-Telangiectasia, investors might find additional context from recent financial data and market performance useful.
According to InvestingPro data, Quince Therapeutics has a market capitalization of $71.84 million USD, reflecting its status as a small-cap biotech company. The stock has shown remarkable momentum recently, with a 144.96% price return over the past month and an 88.55% return over the last year. This surge in stock price aligns with the positive safety data presented at the Child Neurology Society Annual Meeting and the ongoing Phase 3 NEAT study.
However, it's important to note that Quince Therapeutics is currently not profitable, with an adjusted operating income of -$29.52 million USD for the last twelve months as of Q2 2023. This is typical for biotech companies in the development stage, as they invest heavily in research and clinical trials before generating revenue from approved products.
InvestingPro Tips highlight that Quince holds more cash than debt on its balance sheet, which could be crucial for funding ongoing clinical trials and operations. However, the company is also quickly burning through cash, a common challenge for biotech firms developing novel treatments.
Investors should be aware that while the stock is trading near its 52-week high, analysts do not anticipate the company will be profitable this year. This underscores the speculative nature of investing in early-stage biotech companies and the importance of the success of EryDex for Quince's future prospects.
For those interested in a deeper analysis, InvestingPro offers 14 additional tips for Quince Therapeutics, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.